Navigation Links
ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
Date:4/15/2008

er the end of the infusion. Hematology, serum chemistry, and adverse event reporting were performed throughout the study period.

In post hoc analyses, relative to Navelbine, ANX-530 demonstrated a statistically significant reduction in injection site reactions. Notably, the incidence of injection site reactions attributed to Navelbine was consistent with its product label. Furthermore, ANX-530 was determined to be safe and well-tolerated with no significant differences observed in any other safety parameters. Safety data from the study will be published in the 2008 Proceedings of the American Society of Clinical Oncology (ASCO) in connection with ASCO's 2008 Annual Meeting.

ADVENTRX is preparing and intends to submit to the FDA a Section 505(b)(2) New Drug Application (NDA) for ANX-530 in the fourth quarter of 2008.

About ANX-530 (vinorelbine emulsion)

ANX-530 is a novel emulsion formulation of the chemotherapy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the U.S. to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer. Worldwide sales of Navelbine and generic formulations of vinorelbine in 2006 were in excess of $200 million.

Navelbine and its generic equivalents are often associated with injection site reactions, including phlebitis, erythema and pain at the site of injection. Studies have shown these reactions occur in approximately one-third of patients, with 5% of the reactions categorized as severe. ANX-530 is designed to reduce the incidence and severity of these injection site reactions. ADVENTRX's formulation emulsifies vinorelbine into a homogeneous suspension of nanoparticles that is designed protect the venous endothelium during administration into a peripheral vein, thereby reducing irritation associated with administration of the d
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
2. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
3. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
4. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
5. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
6. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
7. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
8. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
9. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... (Nasdaq: SIAL ),announced today it has entered ... This collaboration is expected to support,the development and ... a planned launch of many of these products in ... tools for regenerative medicine,are expected to consist of serum-free ...
... N.J., Nov. 25 Celator Pharmaceuticals today announced that Scott ... 20th Annual Piper Jaffray Health Care Conference in New York ... Jackson will provide a corporate overview and an update on ... held as follows: , , ...
... YORK,Nov. 25 AngioGenex, Inc. (OTC Bulletin Board: AGGX) is ... genes and proteins for the discovery and development of anti-angiogenic ... its 2008 objectives and its key business goals for 2009. ... number of important milestones that it set for itself in ...
Cached Biology Technology:Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine 2Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine 3Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference 2AngioGenex Reviews 2008 Achievements and Sets Goals for 2009 2AngioGenex Reviews 2008 Achievements and Sets Goals for 2009 3
(Date:1/22/2015)... Issued by Small Cap IR. In 2011, Nilson Report,s annual ... merchants on the leading payment cards rose to $135.3 billion ... prepaid cards reached 6.54 billion.  Eight million credit card users ... 2012, and credit and debit card fraud resulted in $11.27 ...
(Date:1/22/2015)... 2015   EyeLock, Inc. , a market leader of iris-based ... Gerber to the new role of Senior Vice President ... development of mobile platforms and wearable solutions for EyeLock,s technologies. ... in the semiconductor industry to his role at EyeLock, with ...
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES debut of ... Robbins will be at the NXT-ID booth January 6th ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... of basic research, scientists at Johannes Gutenberg University Mainz ... the human Usher syndrome and are coming ever closer ... the Usher research group of Professor Dr. Uwe Wolfrum ... repair of mutated genes or the deactivation of the ...
... new generation of bio-based plastic packaging is not only ... traditional plastic packaging. The plastic packaging industry is moving ... every year in the production of plastics equates to ... consumption. Approximately 40 per cent of all plastics are ...
... method for generating stem cells from mature cells promises to ... a barrier to regenerative medicine therapies that would replace damaged ... at the Salk Institute for Biological Studies, allows for the ... as reduces production time by more than half, from nearly ...
Cached Biology News:Ray of hope for human Usher syndrome patients 2Ray of hope for human Usher syndrome patients 3Plastic packaging industry is moving towards completely bio-based products 2Salk scientists develop faster, safer method for producing stem cells 2Salk scientists develop faster, safer method for producing stem cells 3Salk scientists develop faster, safer method for producing stem cells 4
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
Fujifilm Pictro-Color Process for sharp, clear reproduction comparable to silver-halide photography. Photorealistic 400 dpi quality. A4 and A5 output....
... The SearchLight® IR Mouse Cytokine Array ... assay) for the quantitative measurement of 12 ... plasma and culture supernatants. Each well of ... that capture specific cytokines in standards and ...
... This kit is designed for the ... large vector plasmids at any position (for ... included FRT-PGK-gb2-neo-FRT cassette is designed to allow ... eukaryotic cells. It combines a prokaryotic promoter ...
Biology Products: